ACARIX AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3005 SEK | +0.17% |
|
-9.62% | +58.32% |
| 27/05 | Acarix AB Appoints Jeff Thomas as the New Head of US Sales, Effective June 1, 2024 | CI |
| 14/05 | Transcript : Acarix AB, Q1 2024 Earnings Call, May 14, 2024 |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +58.32% | 27.94M | D+ | ||
| -41.30% | 2.9B | C+ | ||
| +24.32% | 1.97B | - | ||
| -8.30% | 1.53B | - | ||
| +27.52% | 1.34B | B+ | ||
| -17.31% | 953M | - | ||
| -28.65% | 817M | - | C- | |
| +2.36% | 807M | - | ||
| -24.15% | 635M | B+ | ||
| +21.70% | 599M | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
- Stock Market
- Equities
- ACARIX Stock
- Ratings Acarix AB
